Azenta vs 10x Genomics
Azenta and 10x Genomics are similar in size: $594m and $643m of revenue in their latest fiscal years. 10x Genomics grew faster (5.2% against 3.6%). 10x Genomics kept more of each dollar of sales as profit: a net margin of -6.8% against -9.4%. Azenta carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | AzentaAZTA, 2025 | 10x GenomicsTXG, 2025 |
|---|---|---|
| Revenue | $594m | $643m |
| Revenue growth | 3.6% | 5.2% |
| Net income | −$55.8m | −$43.5m |
| Operating margin | -4.5% | -9.5% |
| Net margin | -9.4% | -6.8% |
| Return on equity | -3.2% | -5.8% |
| Free cash flow | $38.3m | $130m |
| Cash | $280m | $474m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $0 | — |
| Employees | 3,000 | — |
| Market value | $1.63bn | $8.34bn |
| Price vs our value range | Above our value range | — |
| Moat score | 46 (Moderate) | 33 (Weak) |
| Insider trades, 12 months | 2 buys, 0 sales | 0 buys, 50 sales |